Two‐drug combination benefits patients with chronic lymphocytic leukemia

[1]  T. Shanafelt,et al.  Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. , 2019, The New England journal of medicine.